Vedolizumab Beats Infliximab as Second-Line UC Therapy ...Middle East

Medscape - News
Vedolizumab Beats Infliximab as Second-Line UC Therapy
In patients with ulcerative colitis, vedolizumab outperformed infliximab as a second-line therapy following failure of anti-TNF therapy. Medscape Medical News

Hence then, the article about vedolizumab beats infliximab as second line uc therapy was published today ( ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Vedolizumab Beats Infliximab as Second-Line UC Therapy )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News


Latest News